Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sjemmeri who wrote (4507)	11/9/2005 3:28:29 PM
From: sjemmeri	Read Replies (1) of 4974

11/9/2005 CRXX CombinatoRx prices at low end of revised range CombinatoRx, which is developing medicines built from synergistic combinations of approved drugs, priced its IPO of 6 million shares at $7 on Wednesday morning. The pricing came in at the low end of the company's downwardly revised range of $7 to $9. CombinatoRx's original price range was $10 to $12. SG Cowen was the lead underwriter on the deal. The stock is expected to begin trading on the NASDAQ under the ticker CRXX later on Wednesday.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next